Clinical Trials on Sun Protection Factor in Austria

Total 110 results

Medical University of Vienna

Completed

Optimization of Ventilation Strategies in Preterm and Term Infants in a Single-center Intervention Study

Lung-protective Ventilation | Respiratory Function Monitor

Austria
Medical University of Graz

Completed

Testing of Personal Protective Equipment (PPE) (PPE-Test)

Personal Protective Equipment | Heat Stress

Austria
Medical University of Vienna

Active, not recruiting

Effect Levosimendan Administration on Postoperative NT-proBNP in Cardiac Risk Patients (IMPROVE)

Cardiovascular Risk Factor

Austria
Baxalta now part of Shire

Completed

Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant Reversal

Prothrombin Complex Factor Deficiency

Hungary, Austria
Medical University of Graz

Recruiting

"Pilot Study: Effects of Vibration on Postoperative Early Mobilization of Cardiac Surgery Patients" (CardioVIB)

Frailty | Cardiovascular Risk Factor

Austria
Augenabteilung Allgemeines Krankenhaus Linz

Completed

Effect Aflibercept on Ocular Perfusion

Macular Degeneration | Anti Vascular Endothelial Growth Factor

Austria
Medical University of Vienna

Terminated

The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion

Macular Degeneration | Vascular Endothelial Growth Factor | Regional Blood Flow

Austria
Medical University of Vienna

Unknown

Fluid Status in Valvular Heart Disease

Fluid Overload | Cardiovascular Risk Factor | Valvular Heart Disease

Austria
CSL Behring

Completed

Prothrombin Complex Concentrate for Anticoagulant Reversal

Acquired Coagulation Factor Deficiency

Austria, Germany, Hungary, Israel, Lithuania, Netherlands, Poland, Switzerland
Paracelsus Medical University

Completed

Cardiovascular Risk Markers in Spinal Cord Injured Subjects of the Wheelchair Dancer Study

Cardiovascular Risk Factor | SCI - Spinal Cord Injury

Austria
Medical University of Graz

Completed

ICU Trial in Critical Ill COVID-19 Patients (POINT-C)

Critical Illness | Covid19 | Risk Factor, Cardiovascular | Course Illness

Austria
Flinders University
medac GmbH; University of South Australia

Recruiting

Methotrexate, Blood Pressure and Arterial Function in Rheumatoid Arthritis

Rheumatoid Arthritis | Endothelial Dysfunction | Cardiovascular Risk Factor | Stiffness, Aortic

Australia
University of Texas at Austin
POM Wonderful LLC

Completed

Reversing Muscle Loss With Exercise Training and Daily Consumption of Pomegranate Juice

Sarcopenia | Cardiovascular Risk Factor

United States
Themis Bioscience GmbH

Completed

Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability (V186-001)

Zika Virus

Austria
Themis Bioscience GmbH

Completed

Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (V187-001) (MV-ZIKA-RSP)

Zika Virus Infection

Austria
Moritz Oberndorfer
Merck Gesellschaft mbH, Austria

Completed

Lipid Profile and Diabetes Mellitus in People With HIV

HIV Infections | Diabetes Mellitus | Dyslipidemias | Cardiovascular Risk Factor

Austria
Medical University Innsbruck

Active, not recruiting

Correlation of Artherosclerotic Plaque Volume and Intima Media Thickness With Soluble P-selectin

Coronary Artery Disease | Peripheral Artery Disease | Cardiovascular Risk Factors | Cerebrovascular Disease

Austria
Monash University

Recruiting

The Potential of Carnosine Supplementation in Optimising Cardiometabolic Health

Cardiovascular Risk Factors | Cognitive Function 1, Social | Poor Glycemic Control

Australia
Murdoch Childrens Research Institute
Royal Children's Hospital

Completed

What is the Incidence of an Immune Disorder in Children With Invasive Pneumococcal Disease (IPD)?

Primary Immunodeficiency | Invasive Pneumococcal Disease, Protection Against | Invasive Pneumococcal Disease, Recurrent Isolated, 1 | Invasive Pneumococcal Disease, Recurrent Isolated, 2

Australia, New Zealand
Orphatech Pharmaceuticals, GmbH

Withdrawn

Study of cPMP (Precusor Z) to Treat Molybdenum Cofactor Deficiency (MoCD) Type A

Molybdenum Cofactor Deficiency Type A

Australia
VASCage GmbH
Medical University Innsbruck; Tirol Kiniken GmbH

Completed

Early Vascular Ageing in the YOUth (EVA4YOU)

Cardiovascular Diseases | Vascular Diseases | Hypertension | Obesity | Overweight | Sleep Disorder | Atherosclerosis | Sleep | Headache | Vascular Stiffness | Cardiovascular Risk Factor | Non-Alcoholic Fatty Liver Disease | Life Style | Cardiovascular Pathology

Austria
Novartis Pharmaceuticals

Completed

Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients (B-Confident)

Cryopyrin-associated Periodic Syndromes (CAPS) | Familial Cold Autoinflam Syn (FCAS) | Muckle-wells Syn (MWS) | Neonatal Onset Multisystem Inflam Disease (NOMID)

Switzerland, United States, Germany, Norway, Austria
National Institute of Allergy and Infectious Diseases...

Completed

Phase 1 Study of the Safety, Reactogenicity, and Immunogenicity of AMA1-C1/ISA 720: Blood Stage Vaccine for Plasmodium Falciparum

Malaria

Australia
Pfizer

Completed

TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)

Encephalitis, Tick-Borne

Germany, Austria, Poland
Medicines for Malaria Venture
Q-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer...

Completed

Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048, Part A

Malaria

Australia
Medical University of Vienna
Valneva Austria GmbH

Unknown

Immune Responses After a Booster Immunisation With IXIARO® in Elderly Compared to Young Individuals.

Japanese Encephalitis Vaccine

Austria
Medical University of Vienna

Completed

Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis Vaccination

Tick-borne Encephalitis

Austria
sigma-tau i.f.r. S.p.A.
CPR Pharma Services Pty Ltd, Australia

Completed

Food Interaction Study on the Pharmacokinetics of Eurartesim™ (DHA and PQP)in Healthy Male Adult Volunteers

Malaria, Falciparum

Australia
Elisabethinen Hospital
Baxter Healthcare Corporation; ASOKLIF

Unknown

Evaluation of Immunogenicity of Different Tick Borne Encephalitis (TBE) Fast Protective Traveler Schemes With Inactivated TBE Whole Virus Vaccine (immunisation)

Tick Borne Encephalitis

Austria, Czech Republic
Medicines for Malaria Venture
Nucleus Network Ltd; Southern Star Research Pty Ltd.

Completed

MMV533 Plasmodium Falciparum Volunteer Infection Study

Malaria

Australia
Medicines for Malaria Venture
Q-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer... and other collaborators

Completed

Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent (OZGAM)

Malaria

Australia
Medicines for Malaria Venture
Nucleus Network Ltd; Southern Star Research Pty Ltd.

Completed

A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of a Single Doses of MMV533.

Malaria

Australia
Medicines for Malaria Venture
Q-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; Queensland Institute...

Terminated

A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection (DSMOZ-2)

Malaria

Australia
Themis Bioscience GmbH

Completed

Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine (MV-CHIK-202)

Chikungunya Virus Infection

Austria, Germany
Medicines for Malaria Venture
Nucleus Network Ltd; Southern Star Research Pty Ltd.

Completed

Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of Ruxolitinib With Artemether-lumefantrine

Malaria

Australia
Medicines for Malaria Venture
Q-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer... and other collaborators

Completed

Experimental Falciparum Transmission to Anopheles (EFITA)

Malaria

Australia
GlaxoSmithKline

Terminated

A First Time in Human Study in Healthy Volunteers to Investigate a New Medicine to Treat Malaria

Malaria

Australia
Medicines for Malaria Venture
Q-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer...

Completed

MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects, Part B

Malaria

Australia
Medicines for Malaria Venture
Q-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer...

Completed

A Phase Ib Induced Malaria Infection Study With the Combination of OZ439 and DSM265 (OZ/DSMCombo)

Malaria

Australia
Medicines for Malaria Venture
Queensland Institute of Medical Research

Completed

Effectiveness of OZ439 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Volunteers

Malaria

Australia
Medical University of Vienna
Austrian Science Fund (FWF)

Completed

Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients

Tick Borne Encephalitis

Austria
Medical University of Vienna

Unknown

Application of a TBE-Vaccine in Obese Persons

Tick Borne Encephalitis

Austria
sigma-tau i.f.r. S.p.A.
CPR Pharma Services Pty Ltd, Australia

Completed

A Pharmacokinetic (PK) Trial in Healthy Asian and Caucasian Volunteers Investigating the PK Profile of Eurartesim™

Malaria, Falciparum

Australia
Medicines for Malaria Venture
Q-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer...

Completed

Safety, Tolerability and Antimalarial Activity of Single Doses of OZ439 and PQP

Malaria

Australia
Medicines for Malaria Venture
Q-Pharm Pty Limited

Terminated

MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants

Malaria, Falciparum

Australia
University of Oxford
British Heart Foundation; European Commission; Oxford University Hospitals NHS... and other collaborators

Recruiting

The Oxford Risk Factors And Non-Invasive Imaging Study (ORFAN)

Cardiovascular Diseases | Cardiovascular Risk Factors

United Kingdom, Germany, Belgium, China, United States, Australia, France, Greece, Hungary, Italy, Japan, Korea, Republic of, Netherlands, Romania, United Arab Emirates
Serum Institute of India Pvt. Ltd.
PPD

Completed

Safety Study of Dengushield in Healthy Adults

Dengue | Phase 1

Australia
Valneva Austria GmbH

Completed

Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis

Austria, Germany
Idorsia Pharmaceuticals Ltd.

Completed

Effect of ACT-451840 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Subjects

Healthy Subjects

Australia
Medical University of Vienna

Completed

TBE (Tick-borne Encephalitis) Vaccination in Allergic Patients

Vaccine Responsiveness in Allergy | Vaccine Responsiveness During Allergy De-sensitization Treatment

Austria

Clinical Trials on Sun Protection Factor in Austria

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations